I started Exo Advantage because every clinician should have access to the same high-quality, safe, and affordable protocols that are used by the nation's blood banks and the Red Cross.
Many procedures are not covered by insurance leaving clinicians in the unenviable position of not being able to offer the same care regardless of a patient's ability to pay. It is not unusual for disadvantaged populations to be unable to afford basic introductory regenerative medicine procedures. Many leading regenerative medicine physicians reached out to me to see if I could provide a solution to this problem.
Exo Advantage has addressed this problem head-on. We have developed a one-platform protocol to provide an affordable solution for clinicians and patients.
Please reach out to me if you would like to learn more.
Laura McGillicuddy
President, CEO
Exo Advantage LLC
Andrew McGillicuddy
Andrew McGillicuddy is a pioneer in the field of autologous regenerative medicine with over 25 years of experience. He holds numerous patents and patent applications. He has been involved in several successful businesses and product launches.
Andrew McGillicuddy is the first named inventor of the Cervos line of products including the Key PRP, Lipo Pro, and Marrow Cellutions BMA systems, and was one of the earliest employees of Harvest Technologies. He saved his best work for last and is committed to providing unparalleled capabilities at affordable prices.
Our Mission
To offer superior protocols to the regenerative medicine community.
To significantly expand the capabilities available, such as proteins from plasma(exosomes) and photobiomodulation, without increasing cost.
To offer simple standard protocols based on a common platform.
To dramatically reduce the cost of providing regenerative medicine services while also introducing pricing transparency.
New protocols such as photobiomodulation and exosomes are starting to demonstrate a positive and accretive adjunctive benefit. Other tissues, such as bone marrow aspirate and adipose aspirate, are also increasingly being adopted in regenerative medicine. Common protocols and supplies to work with each tissue improve workflows leading to more reproducible processing results.
Laura and Andrew McGillicuddy started this company to disrupt the regenerative medicine industry, to end ridiculous prices, and to help patients receive the best care. Thank you for your support!